Literature DB >> 3661550

Iron overload and mobilization in long-term hemodialysis patients.

R M Hakim1, J C Stivelman, G Schulman, M Fosburg, L Wolfe, M J Imber, J M Lazarus.   

Abstract

Iron overload from repeated transfusions of RBCs in long-term hemodialysis patients is a problem of increasing clinical significance. We report on the prevalence of and diagnostic criteria for identification of hemodialysis patients with iron overload. In 150 unselected hemodialysis patients, 62 (41%) had ferritin levels greater than 2,000 ng/mL (normal = 10 to 360 ng/mL). In 16 of these patients, accurate transfusion histories were obtained and ferritin levels correlated with calculated transfusional iron burden (r = 0.553, P less than .05). These patients could be divided into two distinct groups on the basis of their response to a single dose (2 g, IV) of deferoxamine: "high" responders had twice the level of feroxamine (the chelated product of deferoxamine and iron) of the "low" responders (P less than .001). High responders also had significantly higher prevalence of the "hemochromatosis" alleles A3, B7, and B14 than a large group of dialysis patients awaiting transplantation (71% v 37%, P less than .001). In two patients with iron overload and clinically significant bone disease, bone histology revealed prominent iron staining at the calcification front. We conclude that transfusional iron overload is a significant clinical problem in long-term hemodialysis patients, that may also be associated with bone pathology.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3661550     DOI: 10.1016/s0272-6386(87)80025-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  The critical role of iron in some clinical infections.

Authors:  J J Bullen; C G Ward; H J Rogers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

2.  Transfusion burden among patients with chronic kidney disease and anemia.

Authors:  Elizabeth V Lawler; Brian D Bradbury; Jennifer R Fonda; J Michael Gaziano; David R Gagnon
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

3.  Recombinant human erythropoietin therapy in children maintained by haemodialysis.

Authors:  S P Rigden; G Montini; M Morris; K G Clark; G B Haycock; C Chantler; R C Hill
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

4.  Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).

Authors:  Wolfgang C Winkelmayer; Aya A Mitani; Benjamin A Goldstein; M Alan Brookhart; Glenn M Chertow
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

5.  A technique for rapid exchange of continuous renal replacement therapy.

Authors:  Peter Yorgin; Marlys Ludlow; Annabelle Chua; Steve Alexander
Journal:  Pediatr Nephrol       Date:  2006-03-14       Impact factor: 3.714

Review 6.  Iron overload cardiomyopathies: new insights into an old disease.

Authors:  P Liu; N Olivieri
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

7.  Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.

Authors:  Robert N Foley; Bryan M Curtis; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-15       Impact factor: 8.237

8.  Blood transfusion, serum ferritin, and iron in hemodialysis patients in Africa.

Authors:  Leonard Kouegnigan Rerambiah; Laurence Essola Rerambiah; Armel Mbourou Etomba; Rose Marlène Mouguiama; Phanie Brunelle Issanga; Axel Sydney Biyoghe; Batchelili Batchilili; Sylvestre Akone Assembe; Joel Fleury Djoba Siawaya
Journal:  J Blood Transfus       Date:  2015-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.